Lonza Completes Expansion of Conjugation Facility in Visp, Switzerland
Basel, Switzerland – Lonza, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, announced today that a planned expansion of its bioconjugation facility in Visp (CH) is complete.
The expansion includes two manufacturing suites and supporting infrastructure. It will support an extended customer portfolio, including companies entering clinical development. The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates.
The new suites complement Lonza’s recent investments and asset extensions in Visp (CH) in mammalian capacity, microbial development, drug product development and manufacturing, and HPAPI payload-linker manufacturing capacity. These continued investments into the Visp (CH) site provide a flexible solution for customers of all sizes at a single location. They are designed to help customers navigate the risks of a complex bioconjugation supply chain. In addition to the two new manufacturing suites, the expansion also includes an increase in process and analytical development and quality control capacity to support future portfolio growth.
Stefan Egli, Vice President, Head of Bioconjugates, Lonza, commented: “The opening of the new bioconjugate manufacturing suites in Visp (CH) reflects our dedication to continuously improving our offering and expertise in line with anticipated market and customer needs. Combined with our offerings across drug substance and drug product manufacturing in small molecules and biologics, our bioconjugation services can support projects from early phase through to late-stage and commercial programs.”
As the leading CDMO for bioconjugates, Lonza offers customers a fully integrated solution, including the different technologies required to deliver safe and reliable bioconjugate products.
Categories
Countries
Latest news
Cepsa to build a new second-generation biofuels plant with an investment of up to 1 billion euros in Palos de la Frontera, Spain
The plant will produce sustainable fuels for aviation, maritime and land transport, enabling CO2 emissions to be reduced by up to 90%. The project reinforces the implementation of its new strategy,...
BASF to invest in its aroma ingredients business by expanding its global production footprint with new plants in China and Ludwigshafen, Germany
New menthol and linalool plants in Ludwigshafen, Germany. Strong commitment to sustainability transformation
To Accelerate European Green Energy Adoption, Uniper Selected Plug to Design the 100MW Electrolyzer Package for the Rotterdam Maasvlakte Plant in The Netherlands
The H2Maasvlakte project will help achieve Uniper's decarbonisation targets to produce green hydrogen by 2026, rapidly expanding that capacity to 500 MW by 2030 at the latest.
VoltH2 receives SDE++ operating subsidy for green hydrogen plants in Terneuzen and Vlissingen The Netherlands
These green hydrogen plants have had environmental permits since Q2 2022 and the projects are now one step closer to realisation thanks to the SDE++ support. After the final investment decision, co...